| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| MR1 & B2M | Biotinylated Human MR1&B2M Complex Protein (MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | 상세 |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute | 상세 |
| SAR-445399 | SAR-445399 | Phase 1 Clinical | Sanofi | Inflammation | 상세 |
| GSK3903371 | GSK3903371 | Clinical | Glaxosmithkline Plc | Neoplasms | 상세 |